Back to Cardiology
Cardiologyv2014Evidence-Based

HCM Risk-SCD

Estimates 5-year risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Helps determine need for implantable cardioverter defibrillator (ICD) in HCM patients.

Clinical Input Parameters

years
Range: 16 — 110 years
mm
Range: 10 — 40 mm
mm
Range: 15 — 70 mm
mmHg
Range: 0 — 200 mmHg
Clinical Assessment
Awaiting Parameters
scd risk
—%
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The HCM Risk-SCD is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within cardiology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Prognostic Index = 0.15939858*(Max wall thickness) - 0.00294271*(Max wall thickness)² + 0.0259082*(LA diameter) + 0.00446131*(Max LVOT gradient) + 0.4583082*(Family history SCD) + 0.82639195*(NSVT) + 0.71650361*(Unexplained syncope) - 0.01799934*(Age); 5-year SCD risk (%) = 1 - 0.998^exp(Prognostic Index)

Clinical Pearls & Practice Notes

  • For patients aged 16 years and older with HCM
  • Not validated for use in pediatric patients (<16 years)
  • Not for use in elite athletes
  • Not for patients with metabolic diseases associated with HCM (e.g., Anderson-Fabry disease)
  • Risk should be reassessed every 1-2 years or when clinical change occurs
  • Additional risk modifiers may be considered in borderline cases

Evidence & Literature Citations

  1. O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439.
  2. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014 Oct 14;35(39):2733-79. doi: 10.1093/eurheartj/ehu284.
  3. O'Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation. 2018 Mar 6;137(10):1015-1023.

Score Interpretation Ranges

Low Risk0 – 3.999 pts

Low 5-year SCD risk

Intermediate Risk4 – 5.999 pts

Intermediate 5-year SCD risk

High Risk6 – 100 pts

High 5-year SCD risk

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.